CorVel's accelerating premium growth (10.7% YoY in 2027Q1) and improving underwriting profitability (combined ratio down to 83.3% from 89.1% in 2024Q4) suggest a fundamentally sound core business.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.67 vs — | $267M vs — |
Q3 2026 Aug 5, 2026 | $0.63 vs — | $260M vs — |
Q2 2026 May 20, 2026 | $0.61 vs — | $249M vs — |
Q1 2026 Feb 3, 2026 | $0.47 vs — | $236M vs — |
CorVel (NASDAQ: CRVL - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Risk and Volatility CorVel has a beta of 0.97,
CorVel launched its CareMC Accelerator for Guidewire ClaimCenter, enabling seamless managed care integration, real-time updates, and workflow efficiency.
CorVel (NASDAQ: CRVL - Get Free Report) and Hinge Health (NYSE: HNGE - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Insider and Institutional Ownership 51.4% of CorVel shares
Wellgistics Health (NASDAQ: MEDS - Get Free Report) and CorVel (NASDAQ: CRVL - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares Wellgistics Health and
Benchmark CRVL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CorVel Corporation (CRVL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $83.16 | $4.24B | 34.69 | 7.03% | 12.02% | 30.2% | — | |
| $125.02 | $3.05B | 19.18 | 3.65% | 16.75% | 12.75% | 1.56% | |
| $21.75 | $311.87M | 10.26 | 2.02% | 6.74% | 4.34% | 6.45% | |
| $1.98 | $19.17M | -0.42 | — | -2209.55% | -148.34% | — | |
| $19.59 | $366.41M | 9.05 | 2.63% | 12.1% | 16.38% | 13% | |
| $0.47 | $15.05M | 0.36 | 4.06% | 1.81% | 1.14% | 40.83% |
CorVel Corporation (CRVL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CorVel Corporation (CRVL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 1, 2026·SEC
May 20, 2026·SEC
Get notified when CRVL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CorVel Corporation (CRVL) stock FAQ — growth, dividends, profitability & financials explained
CorVel Corporation (CRVL) grew revenue by 8.3% over the trailing twelve months, compared with the twelve months before.
Yes. CorVel Corporation (CRVL) earned $121.5M in net income over the trailing twelve months (a 12.0% net margin).
CorVel Corporation (CRVL) had a return on equity (ROE) of 30.2% over the trailing twelve months. That is well above the market's typical 10-15%.
CorVel Corporation (CRVL) has a combined ratio of 85.1%. A ratio below 100% indicates underwriting profitability.
